ArticleComputational and structural biotechnology journal2025
Assessing the role of volumetric brain information in multiple sclerosis progression.
Article in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis is a chronic autoimmune disease that affects the central nervous system. Understanding multiple sclerosis progression and identifying the implicated brain structures is crucial for personalized treatment decisions. Deformation-based morphometry utilizes anatomical magnetic resonance imaging to quantitatively assess volumetric brain changes at the voxel level, providing insight into how each brain region contributes to clinical progression with regards to neurodegeneration. Utilizing such voxel-level data from a relapsing multiple sclerosis clinical trial, we extend a model-agnostic feature importance metric to identify a robust and predictive feature set that corresponds to clinical progression. These features correspond to brain regions that are clinically meaningful in MS disease research, demonstrating their scientific relevance. When used to predict progression using classical survival models and 3D convolutional neural networks, the identified regions led to the best-performing models, demonstrating their prognostic strength. We also find that these features generalize well to other definitions of clinical progression and can compensate for the omission of highly prognostic clinical features, underscoring the predictive power and clinical relevance of deformation-based morphometry as a regional identification tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.